**Supplementary file 3: Reasons for exclusion during full text screening.**

|  |  |  |  |
| --- | --- | --- | --- |
| **Reference** | **Reason for exclusion** | **Title** | **No** |
| [[1](#_ENREF_1)] | Review article | ETC-1002: a future option for lipid disorders?‏ | 1 |
| [[2](#_ENREF_2)] | In vitro and animal study | ETC-1002 Regulates Immune Response, Leukocyte Homing and Adipose Tissue Inflammation via LKB1 Dependent Activation of Macrophage AMPK | 2 |
| [[3](#_ENREF_3)] | Animal study | A novel small molecule, ETC-1002, lowers proatherogenic lipoproteins, reduces adiposity, and improves hepatic steatosis in a hyperlipidemic hamster model | 3 |
| [[4](#_ENREF_4)] | Animal study | AMP-activated protein kinase and ATP-citrate lyase are two distinct molecular targets for ETC-1002, a novel small molecule regulator of lipid and carbohydrate metabolism | 4 |
| [[5](#_ENREF_5)] | Review article | Bempedoic Acid (ETC-1002): an Investigational Inhibitor of ATP Citrate Lyase | 5 |
| [[6](#_ENREF_6)] | Conference abstract | ETC-1002 Lowers LDL-Cholesterol and is Well Tolerated in Hypercholesterolemic Patients Across Four Phase 2a Studies | 6 |
| [[7](#_ENREF_7)] | Animal study | Prevention of Diet-induced Metabolic Dysregulation, Inflammation and Atherosclerosis in Ldlr-/-Mice by Treatment With the ACL Inhibitor ETC-1002‏ | 7 |
| [[8](#_ENREF_8)] | Animal study | Bempedoic Acid Lowers Low Density Lipoprotein-Cholesterol and Attenuates Aortic Atherosclerosis in LDL Receptor-Deficient (LDLR+/- and LDLR-/-) Yucatan miniature pigs | 8 |

References

1. Nikolic, D., Mikhailidis, D. P., Davidson, M. H., Rizzo, M., & Banach, M. (2014). ETC-1002: a future option for lipid disorders? *Atherosclerosis, 237*(2), 705-710.

2. Filippov, S., Pinkosky, S. L., Lister, R. J., Pawloski, C., Hanselman, J. C., Cramer, C. T., et al. (2013). ETC-1002 Regulates Immune Response, Leukocyte Homing and Adipose Tissue Inflammation via LKB1-Dependent Activation of Macrophage AMPK. *Journal of lipid research*, jlr. M035212.

3. Srivastava, R., Hurley, T. R., Brant, A. F., Bradshaw, C. D., Hanselman, J. C., Baker, C., et al. (2011). A novel small molecule, ETC-1002, lowers proatherogenic lipoproteins, reduces adiposity, and improves hepatic steatosis in a hyperlipidemic hamster model. *ATVB Scientific Session, 55*.

4. Pinkosky, S. L., Filippov, S., Srivastava, R. A. K., Hanselman, J. C., Bradshaw, C. D., Hurley, T. R., et al. (2013). AMP-activated protein kinase and ATP-citrate lyase are two distinct molecular targets for ETC-1002, a novel small molecule regulator of lipid and carbohydrate metabolism. *Journal of lipid research, 54*(1), 134-151.

5. Bilen, O., & Ballantyne, C. M. (2016). Bempedoic acid (ETC-1002): an investigational inhibitor of ATP citrate lyase. *Current atherosclerosis reports, 18*(10), 61.

6. Newton, R. S., Ballantyne, C. M., Thompson, P. D., MacDougall, D. E., Hanselman, J. C., Margulies, J. R., et al. (2014). ETC-1002 lowers LDL-cholesterol and is well tolerated in hypercholesterolemic patients across four Phase 2a studies. *Journal of Clinical Lipidology, 8*(3), 339-340.

7. Samsoondar, J. P., Sutherland, B. G., Telford, D. E., Sawyez, C. G., Edwards, J. Y., Filippov, S., et al. (2015). Prevention of Diet-induced Metabolic Dysregulation, Inflammation and Atherosclerosis in Ldlr-/-Mice by Treatment With the ACL Inhibitor ETC-1002. Am Heart Assoc.

8. Burke, A. C., Telford, D. E., Sutherland, B. G., Edwards, J. Y., Sawyez, C. G., Newton, R. S., et al. (2016). Bempedoic Acid Lowers Low Density Lipoprotein-Cholesterol and Attenuates Aortic Atherosclerosis in LDL Receptor-Deficient (LDLR+/-and LDLR-/-) Yucatan Miniature Pigs. *Arteriosclerosis, Thrombosis, and Vascular Biology, 36*(suppl\_1), A18-A18.